Table 1 Characteristics of the included studies
Study | Age (years), I/C | Sample Size, I/C | Intervention | Follow-up (month) | Outcome Measures |
|---|---|---|---|---|---|
Soininvaara 2002 | 83.5 ± 19.9/ 79.7 ± 8.7 | 19 (8/11) | 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate | 12 months | Periprosthetic BMD: proximal femur |
Han 2003 | 63.6 ± 4.1/ 65.2 ± 5.6 | 72 (36/36) | 10 mg/day oral alendronate for 6 months vs. no placebo | 12 months | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |
Wang 2006 | 69.8 ± 5.9/ 69.7 ± 6.7 | 60 (30/30) | 10 mg/day oral alendronate for 6 months vs. no placebo | 3 years | Periprosthetic BMD:distal part of femur and proximal aspect of tibia |
Abu-Rajab 2009 | 68 ± 2.2/ 72 ± 8.1 | 11 (5/6) | 70 mg/week oral alendronate for 6 months vs. a placebo | 2 years | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |
Jaroma 2015 | 66 ± 7.0/ 68 ± 8.2 | 26 (14/12) | 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate | 7 years | Periprosthetic BMD: distal part of femur and proximal aspect of tibia |